PDE inhibitors are useful for acute hemodynamic support in severe heart failure but are contraindicated for long-term use due to increased mortality and arrhythmias.
Answers are grounded in this paper and cite their sources.
Caution against long-term PDE inhibitor use in HF; confirms established risks and leaves open safer inotrope strategies.
Severe acute and chronic heart failure refractory to the conventional regimen continues to be a leading cause of cardiac mortality. Because depression of myocardial contractility is an important pathophysiological factor of heart failure and because the cardiac glycosides possess a low therapeutic value, intense interest is focused on other non-glycoside, non-sympathomimetic positive inotropic agents. These new cardiotonic agents increase the force of action of phosphodiesterase properties and clinical values.
No takes yet. Share an insight, caveat, or question.
Özcan et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: